'First-In-Man' directed pre-clinical development of an anti-cancer agent - CYC065

“首次人体”指导抗癌药物的临床前开发 - CYC065

• 批准号: 101351
• 金额: $ 148.15万
• 依托单位: CYCLACEL LIMITED
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2013
• 资助国家: 英国
• 起止时间: 2013 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=101351
• 关键词: First; Man; directed; pre; clinical

Cyclacel has developed a novel clinical candidate NCE affecting previously unexplored pathways for treatment of acute leukaemia. The compound has a strong rationale for use as a stratified medicine for adult, infant and paediatric indications which have a high unmet medical need. The drug development project encompasses preclinical validation of marker assays for clinical stratification of patients, 'First-In-Man' (FIM)-directed preclinical development, clinical formulation and manufacture of the compound for Phase 1 testing, and testing of combinations with approved and investigational therapeutic agents to facilitate clinical development of the clinical candidate in the target diseases. Success will attract further investment in a UK and EU based development programme, securing additional jobs and will provide access to a new investigational medicine for both adult and infant patients with poor prognosis diseases.

Cyclacel开发了一种新的临床候选NCE，影响以前未探索的急性白血病治疗途径。该化合物具有很强的理由，可作为成人、婴儿和儿科适应症的分层药物使用，这些适应症的医疗需求未得到高度满足。该药物开发项目包括临床前验证，用于患者临床分层的标记物分析，“首次在人”（FIM）指导的临床前开发，用于1期测试的化合物的临床配方和制造，以及与已批准和正在研究的治疗药物的组合测试，以促进临床候选药物在目标疾病中的临床开发。成功将吸引对英国和欧盟开发项目的进一步投资，确保额外的就业机会，并将为患有预后不良疾病的成人和婴儿患者提供一种新的研究药物。